All News
Efficacy and Safety of JAK Inhibitors in Psoriatic Disease
There is a growing body of evidence demonstrating efficacy and safety of JAK inhibitors in patients with moderate-to-severe psoriasis and psoriatic arthritis, according to a systematic review in BMC Rheumatology.
NSAIDs Linked to Heart Failure in Diabetes Patients
Short-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a first-time hospitalisation for heart failure in patients with type 2 diabetes, according to research presented at ESC Congress 2022.
Read Article
Are We Overcautious With TNF Inhibitors in Pregnancy?
What may seem like a prudent approach to treatment of inflammatory bowel disease (IBD) in pregnant women actually represents an overabundance of caution, suggested researchers who found no increased risk from tumor necrosis factor (TNF) inhibitors.
Read Article
Heavy Metal Rheumatology (9.23.2022)
Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website.
Read Article
USPSTF Recommends Screening for Anxiety and Depression
The U.S. Preventive Services Task Force has recommended that general practitioners actively screen and identify anxiety and depression in all adult patients under 65 yrs.
Read Article
Hydroxychloroquine Dosing and SLE Flares
A cohort study examining hydroxychloroquine dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, in accordance with current ophthalmology and rheumatology guidelines, was associated with a higher risk of lupus flares, including moderate or severe lupus flares.
Read Article
CD19 CAR T Cell Therapy in SLE (9.16.2022)
The big news this week: the approval of deucravacitinib (a new class of drug?) for psoriasis; the 2022 ACR guidance on glucocorticoid-induced osteoporosis; a national poll of older adults over the age of 50 who claimed self-reported or doctor-diagnosed arthritis; and much more. Let's review these and other news, journal reports and announcements from this past week.
Read Article
Does Methotrexate Use Lead to Melanoma?
A systematic review suggests that low-dose methotrexate (MTX) use is associated with an increased melanoma risk, but the absolute risk increase could be considered negligible.
Read Article
2022 New ACR Guidance on Glucocorticoid-Induced Osteoporosis (GIOP)
The ACR has updated this guideline and includes recommendations on abaloparatide (PTHrP) and romosozumab, which are newly available since the ACR’s 2017 GIOP guideline.
Read Article
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
